The adoption rate and management of treatment-emergent adverse event during adjuvant abemaciclib treatment in Japanese women with high-risk HR+HER2- early breast cancer

First Author / 第一作者

KAORI TANE

Institution / 單位

Hyogo Cancer Center

Audio / 音訊檔

Author Group / 作者群

Kaori Tane*1, Fumika Taguchi1, Koichi Hirokaga1, Hideki Sakai2, Koji Matsumoto2, Seung Jin Kim1.

Author Group Institution/ 作者群單位

Department of Breast surgery, Hyogo Cancer Center, Akashi, Japan1 Department of Medical oncology, Hyogo Cancer Center, Akashi, Japan2

Category / 主題分類

Clinical Research

Keyword / 關鍵字

Abemaciclib, Adjuvant therapy, Treatment-emergent adverse event, High-risk HR+HER2- early breast cancer

Back to list